Introduces several new products in medicine as of May 2002. Approval by the U.S. Food and Drug Administration of the Neaulasta drug from Amgen for use in decreasing the incidence of infection as manifested by febrile neutropenia; Approval by the U.S. FDA of the antibiotic Avelox IV for the treatment of community-acquired pneumonia, acute bacterial sinusitis acute bacterial exacerbations or chronic bronchitis; Approval by the U.S. FDA of the drug Protonix IV from Wyeth-Ayerst for the treatment of gastroesophageal reflux disease.